PharmaTutor Magazine - May 2017 is released | Subscribe today
Is India hated spot for Cancer Treatments ?
India is one of the highest populating country in the world. As per recent projection by Indian Council of Medical Research (ICMR), in the total number of new cancer cases is expected to reach nearly 17.3 lakh new cases in 2020. Also in India, cancer treatment generally covers lakhs, particularly with certain lung, breast and prostate cancer drugs evaluated on a lakh per dose in some cases. And there is obvious that it should favourite spot for drug marketers. But, believe me it is not!
Only seven oncology drugs have been introduced in India over five years (2010-14), while nearly 50 major therapies have been launched worldwide.
The main reason for this is the cost of newer cancer treatment which is so extravagant that patients of developing country like India cannot afford it. Indian needs some strongest economical support from government, private and public sectors to fill this void gap. Also so far, various Indian governments affordable medicine policies may be hindering companies to even think whether to launch such treatments or not. Actually, Government should take some positive steps towards cancer treatments and encourage pharmaceutical companies to initiate their new cancer treatments launch in country by patent protection and prosperous rights.
As per ICMR, death by cancer will increase 20% in forthcoming time. This is serious concern for Indian drug regulators and health ministry of India.